Five years post-turducken: The Tipline for 18 June 2018

Yesterday was the fifth anniversary of the Supreme Court’s ruling in Federal Trade Commission v Actavis, holding that reverse-payment settlements by pharmaceutical patent-holders can – but do not necessarily – violate US antitrust law. Check out the Cases section of this morning’s Tipline for the latest in the litigation, which is still going on in federal district court. We also have news from deputy assistant attorney general Don Kempf; the FTC’s challenge to Tronox/Cristal; and an unusual jury conclusion that antitrust defendants conspired but should not be liable for damages.

Get unlimited access to all Global Competition Review content